(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
HGV driver recruited others to smuggle migrants - 2A definitive Manual for Well known Fragrances
- 3A Couple of Reasonable Guitars for 2024
- 4Turkey’s intel chief lays out country’s vision for Middle East, world
- 5Comet MAPS faces a make-or-break moment as it dives toward the sun on April 4 — could it shine in the daytime sky?
- Iran war pushes Germany's deficit to 4.2% as growth outlook is cut by 50%
- $2,000 tariff rebate checks? 50-year mortgages? Making sense of Trump's new 'affordability' proposals.
- Extreme Manual for Picking a Camper Van
- Is new Harry Styles music on the way? Fans think so, after a cryptic website and posters pop up.
- Vote In favor of Your Favored Kind Of Vegetable
- Tech for Wellbeing: Applications and Devices for a Better You
- Archaeologists uncover details about the Hjortspring boat's origins
- RFK Jr.'s vaccine panel delays hepatitis B shot vote after chaotic meeting
- Figure out How to Remain Persuaded During Your Internet based Degree Program
